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Abstract
Alpha helices form a critical part of the binding interface for many protein-protein interactions, 
and chemically stabilized synthetic helical peptides can be effective inhibitors of such helix-
mediated complexes. In particular, hydrocarbon stapling of peptides to generate constrained 
helices can improve binding affinity and other peptide properties, but determining the best stapled 
peptide variant often requires laborious trial and error. Here we describe the rapid discovery and 
optimization of a stapled-helix peptide that binds to Mcl-1, an anti-apoptotic protein that is 
overexpressed in many chemoresistant cancers. To accelerate discovery, we developed a peptide 
library synthesis and screening scheme capable of identifying subtle affinity differences among 
Mcl-1-binding stapled peptides. We used our method to sample combinations of non-natural 
amino-acid substitutions that we introduced into Mcl-1 inhibitors in the context of a fixed helix-
stabilizing hydrocarbon staple that increased peptide helical content and reduced proteolysis. 
Peptides discovered in our screen contained surprising substitutions at sites that are conserved in 
natural binding partners. Library-identified peptide M3d is the most potent molecule yet tested for 
selectively triggering mitochondrial permeabilization in Mcl-1 dependent cell lines. Our library 
approach for optimizing helical peptide inhibitors can be readily applied to the study of other 
biomedically important targets.
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An important goal in modern chemical biology is to develop molecules for inhibiting, 
modifying or otherwise regulating protein-protein interactions (PPIs). PPIs control myriad 
biological phenomena in healthy and diseased cells, and differences in interactions in 
different cell states provide therapeutic opportunities. An ability to rapidly identify and 
optimize tight-binding and selective inhibitors of PPIs could change the landscape of 
pharmaceutical discovery and also benefit basic research. Antibodies and other large, 
engineered proteins can be used to block or alter PPIs outside the cell, and human or 
humanized monoclonal antibodies are powerful agents in the laboratory and the clinic.1 But 
developing smaller molecules is also important. Antibodies cannot currently be delivered 
into the cell cytoplasm or nucleus where many important therapeutic targets function. The 
large size of antibodies also limits their access to certain tissues and types of binding sites. 
From this perspective, small molecule or peptide inhibitors of PPIs are attractive, and 
peptides are good candidates for development because they can readily mimic natural 
interaction motifs and achieve a high degree of binding affinity and specificity even at 
interaction sites that lack deep binding pockets.2,3
Peptides composed of natural amino acids can be engineered using library screening coupled 
with DNA sequencing for hit decoding. For example, phage display and cell-surface display 
readily provide access to diverse libraries with 107–1014 members that can be screened for 
target binding.4–8 However, the natural L-amino acids that can be easily encoded using 
genetics sample only a small part of the potentially interesting peptide chemical space. 
Furthermore, many studies have demonstrated that chemical modifications such as 
cyclization and helix crosslinking can dramatically improve peptide binding.9 Although it is 
possible to chemically modify peptides on phage,10,11 synthesis provides the most versatile 
method of generating chemically diverse modified peptides for optimization. A few recent 
studies have demonstrated the chemical synthesis of libraries of cyclic peptides in a one-
bead-one-compound format.12–16 Alpha helical peptides that include i, i+4 or i, i+7 
crosslinks that stabilize helical conformations are another exciting class of peptide-based 
inhibitors that have shown activity against a range of targets.9,17–19 These peptides also have 
the potential to be optimized using combinatorial methods.
Anti-apoptotic Bcl-2 family proteins are an exciting class of targets for which inhibiting 
PPIs is a promising strategy for developing new cancer therapies.20–22 Human anti-apoptotic 
Bcl-2 family proteins, which include Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and Bfl-1, counteract cell 
death signaling using a mechanism that involves binding to and inhibiting pro-apoptotic 
proteins. The anti-apoptotic proteins bind to a helical Bcl-2 homology region (BH3) in the 
pro-apoptotic partners.23 Thus, using BH3 mimetics to neutralize the function of Bcl-2 
family proteins is an attractive strategy to restore apoptotic signaling in cancer cells and 
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enhance the response to currently approved chemotherapeutics. Consistent with this, small 
molecule PPI inhibitors of Bcl-2 and Bcl-xL have shown dramatic effects shrinking tumors 
in mice and are now being tested in several clinical trials with exciting results.24–27 
Amplification of Bcl-2 family protein Myeloid cell leukemia 1 (Mcl-1) is one of the most 
common genetic aberrations that drives the development and maintenance of a variety of 
human cancers, including adult acute myelogenous leukemias, acute lymphoblastic 
leukemias and triple negative breast cancers.28–30 Moreover, Mcl-1 contributes to the 
resistance of cancer cells to chemotherapies. Unfortunately, cancer cells that rely on anti-
apoptotic protein Mcl-1 for survival are not susceptible to inhibition by compounds hat 
target Bcl-2 or Bcl-xL, and despite significant research efforts, small molecule Mcl-1 
inhibitors have not advanced to the clinic.31
Several studies have led to synthetic BH3 motif peptides that bind selectively to Mcl-1 and 
show activity in assays using permeabilized cancer cells.7,8,32,33 BH3 mimics made entirely 
of natural amino acids are intrinsically disordered in the unbound state and undergo α-
helical folding of the BH3 domain upon binding to anti-apoptotic partners. Thus, a number 
of studies have focused on making improved inhibitors by inserting an all-hydrocarbon 
staple into peptides derived from the BH3 motifs of Bcl-2 family proteins. Such an approach 
led to a 20-fold improvement in binding of a Mcl-1 targeting BH3 peptide.33 In recent years, 
peptides with improved binding to Mcl-1 have been developed,8 and these are also likely to 
benefit from stabilization using a stapling strategy. When optimizing staple-modified 
peptides, synthetic iteration is required to vary sequence composition, length and charge to 
achieve optimal solubility, structural stability and binding activity.34–37 Importantly, 
modification of the peptide may be required to compensate for changes introduced by 
stapling.
Here we describe a rapid design approach that applies hydrocarbon stapling to a potent lead 
peptide and then uses a specialized one-bead-one-compound library to perform further 
optimization. Working with the MS1 peptide, which displays high affinity and specificity for 
Mcl-1, we first identified favorable stapling positions along the BH3 sequence.8 Next, by 
applying a new library synthesis protocol that allowed us to evaluate a diverse library of 
peptides that include a chosen staple, we identified Mcl-1 selective binders using a screen 
for binding affinity and specificity. Our synthetic library of stabilized peptides included non-
natural amino acids that promoted the discovery of protease resistant inhibitors and allowed 
us to access binding crevices not accessible to natural amino-acid side chains. The 
effectiveness of our approach is supported by our identification of molecules that achieve 
exceptionally tight and specific Mcl-1 targeting and show the greatest activity yet observed 
for inducing mitochondrial permeabilization in BH3 profiling assays of Mcl-1 dependent 
cancer cells.
Results and Discussion
Peptide MS1 was selected from a Bim BH3-based library using yeast-surface display, as 
reported by Foight et al.; this peptide binds to Mcl-1 with high affinity and selectivity over 
other anti-apoptotic proteins (Table 1 and Table S1).8 Hydrocarbon stapling, which involves 
installing a covalent, hydrophobic, olefin-bearing linker to connect sequential turns of an 
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alpha helix, has been shown to increase the stability and cellular permeability of peptides 
that bind to protein targets17,38; stapling also increases binding affinity in some cases.39 To 
improve the binding and helicity of MS1 while minimizing its molecular weight, we made a 
truncated sequence and generated a panel of stapled variants to identify staple locations that 
maintained or enhanced binding activity (Figure S1). Three variants with staple positions 
that replaced key hydrophobic or charged residues at the binding interface showed impaired 
binding, but four stapled MS1 variants including M1d resulted in improved binding. The 
staple location in peptide M1d, which replaces Asn at 4b and Ala at 4f with the non-natural 
amino acids required for crosslinking, corresponds to a position previously shown to 
promote binding to Mcl-1 in a peptide called Mcl-1-SAHBD (see Figure S1 and Table 1 for 
sequences and position notation). Interestingly, the crystal structure of Mcl-1 bound to 
Mcl-1-SAHBD shows hydrophobic contacts made between the staple atoms and the edge of 
the Mcl-1 binding groove that likely contribute to the improved affinity (PDB ID: 3MK8).33 
The secondary structure of M1d was measured by circular dichroism, showing that M1d is 
~3-fold more helical in solution than unstapled MS1 (Figure 1a). The hydrocarbon stapling 
strategy also improved Mcl-1-binding affinity and increased peptide resistance to 
proteolysis, in comparison to unstapled MS1 (Figure 1). Having determined that M1d has 
attractive properties as a lead stapled peptide inhibitor, we considered strategies to optimize 
it further.
Although M1d is able to compete effectively for binding with a peptide corresponding to the 
BH3 region of native Bim, structural modeling suggested that M1d may not be maximally 
exploiting the available binding opportunities at three helix positions: 2e, 3a and 3b. 
However, the virtually unlimited hydrocarbon-stapled sequence variations that can be 
studied present a challenge. To date, hydrocarbon stapled peptides have typically been 
rationally optimized by iterative mutagenesis. Obtaining tight-binding and biologically 
active molecules often requires many rounds of laborious synthesis and stapling of different 
candidates. To accelerate the discovery of therapeutic peptides, we extended the application 
of one-bead-one-compound (OBOC) libraries40 by applying ring–closing metathesis 
reaction (RCM)41 to make libraries of BH3-like stapled peptides that can be sequenced 
using standard mass spectroscopy methods (Scheme 1).
To establish conditions that would produce a high-quality stapled peptide library suitable for 
analysis without purification (Figure S2), and to develop efficient on-bead competition 
screening procedures, we synthesized a first-generation 128-member stapled library based 
on a stapled Bim BH3 peptide that contains an i, i+4 all-hydrocarbon crosslink on the 
nonbinding surface of the α-helix (library LA) (Supporting Information). Library LA 
incorporated a number of mutations that have been studied previously to serve as controls, 
and it was designed so that all members had unique masses.7,8,32 Installation of a staple into 
peptides requires incorporation of two appropriately spaced α-4-pentenyl alanine residues, 
with defined stereochemical configuration, followed by RuIV-catalyzed RCM on the 
TentaGel resin.42 Ruthenium mediated olefin metathesis is fully compatible with solid-phase 
peptide synthesis and can be used in a synthetic library. However, excess ruthenium catalyst 
interferes with fluorescence-based on-bead screening and thus must be removed from beads 
prior to the screen. Here, this was accomplished using tris(hydroxymethyl)phosphine.
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Library LA was screened for binding to Mcl-1 and Bcl-xL. Bcl-xL is a paralog of Mcl-1 and 
an undesired interaction target for candidate Mcl-1 inhibitors. Mcl-1 and Bcl-xL have the 
lowest sequence identity among five Bcl-2 family pro-survival proteins, but many BH3 
peptide ligands bind indiscriminately to both of these proteins.7,43 When screening for 
Mcl-1 binding, we performed counter screening against Bcl-xL (and vice versa) to 
incorporate specificity criteria directly in our screens. The Mcl-1 screen led to isolation of 
Mcl-1 specific ligands that did not bind to Bcl-xL at micromolar concentration. The library 
synthesis was optimized to determine an appropriate ligand density (0.25 mmol/g) on the 
bead surface that allowed identification of the most active ligands in a narrow range of low-
nanomolar dissociation constants. In addition, exhaustive testing of buffers and additives 
indicated that a blocking buffer composed of 1000-fold excess cell lysate greatly reduced the 
amount of nonspecific binding.44 Our screen entailed bead blocking, incubation with 
biotinylated Mcl-1 (BioMcl-1) and unlabeled Bcl-xL, washing, incubation with streptavidin-
coated quantum dots (Qdots-SA605), and visualization using a fluorescence microscope. 
173 hit peptides, which were selected manually under the microscope, were cleaved from 
the beads and identified using mass spectrometry. We isolated 96 BH3 peptides specific for 
binding Mcl-1 in preference to Bcl-xL and 77 with the opposite specificity (Figure 2). Both 
the stapling chemistry and subsequent tests for binding were carried out with peptides bound 
to resin, with one unique peptide per bead.
The effects of residue substitutions in stapled peptides isolated from library LA were 
consistent with results from previously reported mutational analyses of non-cyclized 
peptides. When screening for selective binding to Mcl-1 vs. Bcl-xL (or Bcl-xL vs. Mcl-1) we 
observed enrichment of residues previously implicated as important for binding specificity 
(Figure 2 and Supporting Information). For example, at position 2e, Mcl-1 accommodates a 
range of amino acids, including Val, Pro and Thr. In contrast, Bcl-xL has a strong preference 
for Gly and Ala.8,33 We mutated this position to Ala or Thr and found, as expected, that Thr 
was selected more frequently than Ala when screening for selective Mcl-1 binding; the 
opposite preference was observed when screening for Bcl-xL selective binding. Mutation of 
Tyr to Lys at 4e is known to disfavor Mcl-1 binding and confer a preference for interaction 
with Bcl-xL.32 We also observed this effect in stapled peptides; Lys was more prevalent at 4e 
in the library screened for binding to Bcl-xL than in the library screened for binding to 
Mcl-1. More generally, position 3e is typically occupied by small amino acids in native BH3 
sequences and does not tolerate substitution with residues larger than Gly, Ala or Ser for 
either Mcl-1 or Bcl-xL binding. In parallel to this result for non-stapled peptides, an absolute 
selection of Gly over Glu was observed for stapled peptides at position 3e. Other examples 
of good agreement between the library screening results and prior studies are listed in the 
Supporting Information. Selected hit peptides were also confirmed to bind to Mcl-1 in 
solution when not attached to beads (Supporting Information). These observations provided 
evidence that our stapled peptide library screen can efficiently isolate peptides with desired 
binding properties.
To apply library-based optimization to M1d, we prepared 108 stapled peptides designed to 
be enriched in Mcl-1 binders (library LB). Positions 2e, 3a and 3b were diversified with 3, 4 
and 9 amino acids, respectively, varying the residue size, hydrophobicity and/or charge 
(Table 1). Many of the side chains were chosen to be hydrophobic to favor hydrophobic 
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contacts with Mcl-1. We also introduced known helix-inducing side chains to improve the 
helical content of stapled peptides, which is expected to be poor at the peptide N-terminus 
because of two Gly residues in the MS1 template. To choose residues for the mutation sites, 
we used the large amount of mutational data from SPOT arrays and side-chain scanning of 
BH3 peptides.7,8,32 We also analyzed structures of Mcl-1 bound to different BH3 variants 
using Bioluminate (version 1.9, Schrödinger, LLC, New York, NY, 2015) to select non-
natural side chains for the library. We incorporated non-natural functionalities that we 
predicted could make contacts with Mcl-1 that cannot be satisfied by natural side chains. LB 
was sorted for binding to Mcl-1 in two rounds of competition screening in which beads were 
selected that could bind to Mcl-1 in the presence of 12.5- or 50-fold higher concentration of 
Bcl-xL.
LB was initially screened under conditions optimized for library LA: 0.2 μM BioMcl-1 in 
presence of 2.5 μM myc-tagged Bcl-xL (mycBcl-xL). However, for LB, we used a large-
particle flow cytometer that permits fluorescence-based sorting of up to 300 beads/s. The 5% 
of beads with the highest fluorescence intensities were sorted into 96-well plates (Figure 
S3). Beads were washed and then re-screened using more stringent conditions: 0.05 
μM BioMcl-1 plus 2.5 μM mycBcl-xL. After incubation with streptavidin coated quantum 
dots, beads were washed and visualized using a fluorescence microscope. The 170 brightest 
beads from a pool of ~1,000 were isolated manually. MALDI mass spectrometry confirmed 
that the selected beads included 6 different sequences out of the possible 108 stapled BH3 
peptides (Table 1). Sequences M1d (32 beads), M2d (48 beads), and M3d (38 beads) were 
chosen for further analysis. Interestingly, M2d and M3d incorporate previously untested 
unnatural side chains at positions 2e and 3a (Table 1). These positions are highly conserved 
in known BH3 motifs as alanine/glycine and leucine, respectively. M2d and M3d were tested 
in solution in competition with a fluorescently labeled Bim BH3 peptide for binding to five 
human Bcl-2 paralogs (Figure 1b,c and Figure S4). The competition experiments indicated 
that M2d and M3d are both highly selective for Mcl-1 over 4 other anti-apoptotic family 
members and are both tighter binders of Mcl-1 than is M1d (Figure 1b,c). These peptides 
competed with fluoresceinated Bim 21mer for Mcl-1 binding with IC50 values of 106 ± 12 
nM and 72 ± 11 nM, for M2d and M3d respectively (compare with 350 nM for M1d and 811 
nM for MS1).
Position 2e is usually conserved as small (alanine, glycine, serine) in natural BH3 
sequences. However, previous studies have shown that Mcl-1 can bind BH3 peptides with 
bulkier threonine or leucine residues at this site.8,33 Our results show that, likewise, 
introducing the larger, branched 2-aminoisobutyric acid (Aib) at the 2e position in M2d and 
M3d is not only well tolerated but increases binding affinity for Mcl-1. A model of M3d-
peptide bound to Mcl-1, built using Bioluminate and based on PDB structure 3MK8,33 
shows how two methyl groups can form contacts with Mcl-1 (Figure S5). Peptide M3d also 
includes Cha at 3a. The selection of Cha at 3a was not easily anticipated because leucine is 
universally conserved at this site in native BH3 domains and substitution with any residue 
other than Ile is highly destabilizing according to SPOT array experiments.7 Comparing our 
molecular model of M3d to the binding of a 21-mer BH3 peptide derived from Mcl-1 (PDB 
ID: 3MK8) demonstrates that the Cha side chain can fill more of the p2 binding pocket of 
Mcl-1 than can the conserved Leu, which occupies only the upper part of this pocket (Figure 
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1e). This pocket in Mcl-1 has been observed to accommodate small molecule ligands,45–47 
however, these molecules do not make the additional contacts that can be achieved by a BH3 
peptide, including interactions made by hydrophobic side chains at 3d and 4a. The improved 
contacts of M3d result in increased potency, providing a 5-fold decrease in IC50 for Mcl-1 
binding compared to M1d, and an ~11-fold decrease compared to the original MS1 peptide 
(Figure 1b).45
We used biolayer interferometry to study the binding of M2d and M3d to Mcl-1 (Figure 1f, 
S6 and Table S2). We generated biotinylated stapled peptides and attached these to a 
streptavidin-modified probe surface. Quantification of binding and dissociation kinetics 
established that enhanced binding of M2d and M3d to Mcl-1 arises from slower off-rates 
compared to M1d (6- and 16-fold, respectively). Interestingly, the observed trend for binding 
affinities was paralleled by the measured helicity (Figure 1a). M2d and M3d are more helical 
than M1d when unbound, with mean residue ellipticities (MREs) at 222 nm of 15,450 and 
21,000 deg cm2 dmol−1, respectively, compared to 11,590 for M1d. Therefore, increases in 
helicity can be attributed to both non-natural amino-acid substitutions: Aib at 2e and Cha at 
3a.48,49
All of the stapled MS1 variants that we tested were more protease resistant than un-
metathesized M1d, which is a key pharmacologic advantage of the stapling approach. 
Unstapled M1d has a half-life 2–6-fold shorter than the corresponding stapled peptides 
(Figure 1d). Notably, the protease resistance analysis revealed longer half-lives for both M2d 
and M3d compared to M1d, indicating the utility of introducing helix-promoting and/or 
bulky non-natural amino acids into a stapled peptide for maximizing protease resistance.
Finally, we performed BH3 profiling to test the function of stapled variants of MS1 in cells. 
A whole-cell BH3 profiling experiment quantifies the dependence of cancer cell 
mitochondrial integrity on specific anti-apoptotic proteins and can be predictive of cellular 
responses to chemotherapy.50,51 In this assay, permeabilized cells are stained with dye JC1 
to monitor mitochondrial membrane integrity in response to increasing doses of BH3 
peptides. We used this assay to test the specificity of our Mcl-1-binding stapled peptides in 
cell lines with different established dependencies on Bcl-xL and Mcl-1. Mcl-1/Myc 2640 is 
an engineered murine leukemia cell line overexpressing murine Mcl-1 and Myc, and MDA-
MB 231 is a human breast cancer cell line with a primed Bcl-xL-dependent profile.50,52 By 
BH3 profiling using native BH3 peptides from Bad and NoxaA, we confirmed cell line 
dependencies on these anti-apoptotic proteins (Figure S7). Both M1d and M2d showed 
Bax/Bak independent activity in Bax/Bak deficient cells, indicating non-specific toxicity 
(Figure S8). However, peptide M3d showed no activity in Bax/Bak negative cells, consistent 
with an on-target mechanism,[17] and was remarkably potent when tested on Mcl-1/Myc 
2640, with an EC50 value of 27 nM (Figure 3). Thus, the Mcl-1-dependent cell line was 
much more sensitive to M3d than to MS1 and the natural BH3 NoxaA (Figures 3). The 
specificity of M3d was confirmed by the much higher EC50 observed for the Bcl-xL 
dependent cell line MDA-MB 231 (no detectable deplorization up to 400 nM, Figure S8a).
In conclusion, we demonstrated new library synthesis chemistry that can be used to make 
diverse stapled helical peptides that are suitable for on-bead testing. By applying this 
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powerful method, we tailored highly stable, potent and selective Mcl-1 inhibitors. Using 
competition screening of stapled peptides, we identified novel molecules with low 
nanomolar binding affinity for Mcl-1 and greater than 1000-fold selectivity over other Bcl-2 
paralogs. Our tightest-binding peptide, M3d, including hydrophobic and helix-inducing 
unnatural moieties, showed potent activity only in an Mcl-1 dependent cell line. We 
demonstrated the feasibility of combining peptide post-modification with one-bead-one-
compound synthesis, which accelerates the design and optimization of novel chemically 
modified peptidic inhibitors. We anticipate that this approach will find utility in other stapled 
peptide discovery projects that target important biomedical proteins. For example, exciting 
progress identifying stabilized peptides that bind to G-protein-coupled receptors53, apoptosis 
regulators MDM2/MDMX54, and epidermal growth factor receptor tyrosine kinases55 
provide examples of cases where our method can be used to drive further improvements in 
binding.
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Figure 1. 
a) Circular dichroism analysis of unmodified and stapled variants. b) Competition of stapled 
peptides with fluorescently labeled 21mer Bim-BH3 (25 nM) for binding to Mcl-1. Error 
bars show standard errors for three experiments. c) Competition of M3d with fluorescently 
labeled 21mer Bim-BH3 (25 nM) for binding to Mcl-1, Bfl-1, Bcl-w, Bcl-xL or Bcl-2. Error 
bars show the standard error of four replicates. d) Half-lives of unstapled and stapled 
peptides exposed to chymotrypsin. e) Overlay of the leucine side chain at position 3a in 
Mcl-1 SAHBD (green side chain, PDB 3MK8) with the cyclohexylalanine side chain in M3d 
(yellow side chain, model based on 3MK8) illustrates how these ligands occupy the P2 
pocket of Mcl-1. f) Kinetic analysis of M1d, M2d and M3d binding to Mcl-1, using biolayer 
interferometry.
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Figure 2. 
Sequence logos for populations of peptides from library LA screening. 96 Mcl-1 specific 
stapled peptides were identified from competition screens using a mixture 
of BioMcl-1:mycBcl-xL (1:50). 77 Bcl-xL-specific peptides were identified in competition 
screening using BioBcl-xL:mycMcl-1 (1:50). The side chains at the 3c and 3g positions, 
marked X, were replaced with cross-linked α-4-pentenylalanine groups. Mutations were 
made at positions 2d, 2e, 2g, 3b, 3e, 4a and 4e. Figures were made using WebLogo.
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Figure 3. 
Depolarization of the mitochondrial membrane of Mcl-1 2640 cells in response to treatment 
with different BH3 peptides.
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Scheme 1. 
Overview of a stapled-peptide library screen. Linear peptides synthesized on resin are 
cyclized using 1st generation Grubbs catalyst, and excess catalyst is removed by washing 
with tris(hydroxymethyl)phosphine. X1, X2 and X3 comprise the variable region. The one-
bead-one-compound library of stapled peptides is incubated with a mixture of biotinylated 
target protein and non-biotinylated competitor to identify selective binders. Cyclized 
peptides that bind the target are visualized using a fluorescence microscope and then 
decoded by MALDI-TOF mass spectrometry.
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Table 1
Alignment of parent peptides MS1 and M1d with library LB and selected Mcl-1-binding peptides from LB.
S5= α-4-pentenyl alanine, J= Aminoisobutyric acid (Aib), Z= Cyclohexylalanine (Cha), B= Norleucine (substituted for methionine to optimize 
activity of the ruthenium catalyst), X1 = Thr, Val, Aib, X2 = Phe, 5F-Phe, Cha, Leu, X3 = Arg, Asp, Gln, Trp, Tyr, Aib, D-Phenylglycine, α-
methyl-L-leucine, α-methyl-L-phenylalanine.
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